Anti-Resorptive osteonecrosis of the jaws

Facts forgotten, questions answered, lessons learned

Eric Carlson, Benjamin J. Schlott

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Osteonecrosis of the jaws associated with bisphosphonate and other anti-resorptive medications (ARONJ) has historically been a poorly understood disease process in terms of its pathophysiology, prevention and treatment since it was originally described in 2003. In association with its original discovery 11years ago, non-evidence based speculation of these issues have been published in the international literature and are currently being challenged. A critical analysis of cancer patients with ARONJ, for example, reveals that their osteonecrosis is nearly identical to that of cancer patients who are naive to anti-resorptive medications. In addition, osteonecrosis of the jaws is not unique to patients exposed to anti-resorptive medications, but is also seen in patients with osteomyelitis and other pathologic processes of the jaws. This article represents a review of facts forgotten, questions answered, and lessons learned in general regarding osteonecrosis of the jaws.

Original languageEnglish (US)
Pages (from-to)171-191
Number of pages21
JournalOral and Maxillofacial Surgery Clinics of North America
Volume26
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Osteonecrosis
Jaw
Bisphosphonate-Associated Osteonecrosis of the Jaw
Osteomyelitis
Pathologic Processes
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Otorhinolaryngology

Cite this

Anti-Resorptive osteonecrosis of the jaws : Facts forgotten, questions answered, lessons learned. / Carlson, Eric; Schlott, Benjamin J.

In: Oral and Maxillofacial Surgery Clinics of North America, Vol. 26, No. 2, 01.01.2014, p. 171-191.

Research output: Contribution to journalReview article

@article{74e38c9ba87145049310b201c0a29aaf,
title = "Anti-Resorptive osteonecrosis of the jaws: Facts forgotten, questions answered, lessons learned",
abstract = "Osteonecrosis of the jaws associated with bisphosphonate and other anti-resorptive medications (ARONJ) has historically been a poorly understood disease process in terms of its pathophysiology, prevention and treatment since it was originally described in 2003. In association with its original discovery 11years ago, non-evidence based speculation of these issues have been published in the international literature and are currently being challenged. A critical analysis of cancer patients with ARONJ, for example, reveals that their osteonecrosis is nearly identical to that of cancer patients who are naive to anti-resorptive medications. In addition, osteonecrosis of the jaws is not unique to patients exposed to anti-resorptive medications, but is also seen in patients with osteomyelitis and other pathologic processes of the jaws. This article represents a review of facts forgotten, questions answered, and lessons learned in general regarding osteonecrosis of the jaws.",
author = "Eric Carlson and Schlott, {Benjamin J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.coms.2014.01.005",
language = "English (US)",
volume = "26",
pages = "171--191",
journal = "Oral and Maxillofacial Surgery Clinics of North America",
issn = "1042-3699",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Anti-Resorptive osteonecrosis of the jaws

T2 - Facts forgotten, questions answered, lessons learned

AU - Carlson, Eric

AU - Schlott, Benjamin J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Osteonecrosis of the jaws associated with bisphosphonate and other anti-resorptive medications (ARONJ) has historically been a poorly understood disease process in terms of its pathophysiology, prevention and treatment since it was originally described in 2003. In association with its original discovery 11years ago, non-evidence based speculation of these issues have been published in the international literature and are currently being challenged. A critical analysis of cancer patients with ARONJ, for example, reveals that their osteonecrosis is nearly identical to that of cancer patients who are naive to anti-resorptive medications. In addition, osteonecrosis of the jaws is not unique to patients exposed to anti-resorptive medications, but is also seen in patients with osteomyelitis and other pathologic processes of the jaws. This article represents a review of facts forgotten, questions answered, and lessons learned in general regarding osteonecrosis of the jaws.

AB - Osteonecrosis of the jaws associated with bisphosphonate and other anti-resorptive medications (ARONJ) has historically been a poorly understood disease process in terms of its pathophysiology, prevention and treatment since it was originally described in 2003. In association with its original discovery 11years ago, non-evidence based speculation of these issues have been published in the international literature and are currently being challenged. A critical analysis of cancer patients with ARONJ, for example, reveals that their osteonecrosis is nearly identical to that of cancer patients who are naive to anti-resorptive medications. In addition, osteonecrosis of the jaws is not unique to patients exposed to anti-resorptive medications, but is also seen in patients with osteomyelitis and other pathologic processes of the jaws. This article represents a review of facts forgotten, questions answered, and lessons learned in general regarding osteonecrosis of the jaws.

UR - http://www.scopus.com/inward/record.url?scp=84899895485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899895485&partnerID=8YFLogxK

U2 - 10.1016/j.coms.2014.01.005

DO - 10.1016/j.coms.2014.01.005

M3 - Review article

VL - 26

SP - 171

EP - 191

JO - Oral and Maxillofacial Surgery Clinics of North America

JF - Oral and Maxillofacial Surgery Clinics of North America

SN - 1042-3699

IS - 2

ER -